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Abstract 
Zeb1, a zinc finger E-box binding homeobox epithelial-mesenchymal (EMT) 
transcription factor, confers properties of ‘stemness’, such as self-renewal, in 
cancer. Yet little is known about the function of Zeb1 in adult stem cells. Here, 
we used the hematopoietic system, as a well-established paradigm of stem cell 
biology, to evaluate Zeb1 mediated regulation of adult stem cells. We employed 
a conditional genetic approach using the Mx1-Cre system to specifically 
knockout (KO) Zeb1 in adult hematopoietic stem cells (HSCs) and their 
downstream progeny. Acute genetic deletion of Zeb1 led to rapid onset thymic 
atrophy and apoptosis driven loss of thymocytes and T cells. A profound cell-
autonomous self-renewal defect and multi-lineage differentiation block was 
observed in Zeb1 KO HSCs. Loss of Zeb1 in HSCs activated transcriptional 
programs of deregulated HSC maintenance and multi-lineage differentiation 
genes, and of cell polarity, consisting of cytoskeleton, lipid metabolism/lipid 
membrane and cell adhesion related genes. Notably, Epithelial cell adhesion 
molecule (EpCAM) expression was prodigiously upregulated in Zeb1 KO 
HSCs, which correlated with enhanced cell survival, diminished mitochondrial 
metabolism, ribosome biogenesis, and differentiation capacity and an activated 
transcriptomic signature associated with acute myeloid leukemia (AML) 
signaling. ZEB1 expression was downregulated in AML patients and Zeb1 KO 
in the malignant counterparts of HSCs - leukemic stem cells (LSCs) - 
accelerated MLL-AF9 and Meis1a/Hoxa9-driven AML progression, implicating 
Zeb1 as a tumor suppressor in AML LSCs. Thus, Zeb1 acts as a transcriptional 
regulator in hematopoiesis, critically co-ordinating HSC self-renewal, apoptotic 
and multi-lineage differentiation fates required to suppress leukemic potential 
in AML. 
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Introduction 
 
Epithelial-mesenchymal transition (EMT) is a complex process that organizes 
specific changes in cellular fate and phenotype and is usually accompanied by 
loss of cell polarity and adhesion and increased locomotion (1). EMT is an 
important step in embryonic development and regeneration, which largely 
promotes a program of cellular plasticity and migration (2). This program is 
regulated by specific transcription factors (TFs), such as members of the ZEB, 
SNAI, and TWIST families. To this end, Zeb1, a zinc finger TF that binds to E-
box motifs, has been implicated in myogenesis (3-6), neuronal development 
and differentiation (7-10), post gastrulation embryogenesis (11) and T-cell 
development (12, 13). 
 
It has also been posited that EMT is a critical regulator in cancer pathogenesis 
and, in particular, cancer stem cell behavior (14-16), which facilitates cancer 
cells becoming more metastatic with resultant tumor progression (17). 
Abundant evidence shows that Zeb1 regulates stem cell properties in cancer 
including self-renewal (18-20). While it is established that Zeb1 regulates 
expression of multiple stem cell-associated transcription factors, including 
those with oncogenic potential, such as BMI1, KLF4, and SOX2 (19, 21), and 
that loss of Zeb1 promotes cellular differentiation during development of the 
embryonic CNS (9), and skeletal muscle (22), the wider role of Zeb1 in normal 
stem cell fate decisions remains unclear. 
 
 4 
By exploiting a mouse model engineered to contain conditional alleles of Zeb1 
and an inducible Mx-1-Cre (Zeb1fl/fl;Mx1-Cre+) (23), where Zeb1 expression can 
be deleted in hematopoietic stem cells (HSCs) and their progeny by 
administering polyinosinic-polycytidylic acid (pIpC), we used the hematopoietic 
system, as an established stem cell model, to evaluate Zeb1 mediated 
regulation of somatic stem cells. Herein, we identify Zeb1 as a crucial, 
indispensable regulator of adult T cell maturation and differentiation. In a 
broader context, as judged by conditional deletion within the hematopoietic 
system, we identify Zeb1 as an essential transcriptional repressor balancing 
adult stem cell self-renewal, apoptotic and global, multi-lineage differentiation 
fates of stem cells. Finally, we find that Zeb1 mediated regulation of these stem 
cell fates is required to suppress malignancy in the context of acute myeloid 
leukemia (AML).   
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Results 
Acute conditional deletion of Zeb1 reduces the frequency of MAC1+ 
myeloid cells and CD8+ memory T cells 
Zeb1 expression has been observed in hematopoietic cells from bone marrow 
(BM), thymus, spleen, fetal liver and lymph nodes (12, 24). However, Zeb1 
expression pattern in different subsets of hematopoietic cells, including 
hematopoietic stem and progenitor cells (HSPCs), remains unclear.  We 
therefore conducted Q-PCR analysis of Zeb1 expression in hematopoietic cell 
compartments prospectively isolated by fluorescent-activated cell sorting 
(FACS). Zeb1 was expressed at high levels in stem and progenitor cells (HSC, 
MPP (Multipotent progenitor), HPC1 (hematopoietic progenitor cell 1), and 
HPC2 (hematopoietic progenitor cell 2)) and in terminally differentiated cells 
(myeloid, erythroid, B, and T lineages) whereas it was lower in committed 
myeloid and lymphoid progenitors (CMP (common myeloid progenitors), GMP 
(granulocyte-monocyte progenitors), MEP (megakaryocyte-erythroid 
progenitors), CLP (common lymphoid progenitors)) (Figure 1A).  
 
To evaluate the genetic requirement for Zeb1 in adult HSCs, their progenitors 
and fully differentiated blood and immune cells, we bred mice harboring 
conditional alleles of Zeb1 (Zeb1fl/fl mice) (23) with Mx1-Cre (25) to obtain either 
Zeb1fl/fl;Mx1-Cre+/- or control (Zeb1fl/fl;Mx1-Cre-/-) mice and administered pIpC 
on alternate days for 10 days to achieve deletion of Zeb1 (Zeb1-/-). 
Hematopoiesis in control or Zeb1-/- mice was analyzed 14 days after the last 
dose of pIpC (Figure 1B). Zeb1 was partially deleted in total BM cells (Figure 
1C). To assess whether Zeb1 was completely deleted in HSCs from BM, we 
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prospectively isolated Lin- SCA-1+ C-KIT+ (LSK) cells (that contain HSCs) and, 
by genomic PCR, observed complete deletion of Zeb1 (Figure 1C). Similarly, 
C-KIT+ cells, which constitute both HSCs and committed myeloid and lymphoid 
progenitors, were fully deleted for Zeb1 (Figure 1D). In contrast, only partial 
deletion of Zeb1 was observed in terminally differentiated T and B cells isolated 
from the spleen (Figure 1D), suggesting that incomplete deletion observed in 
BM cells may be ascribed to these cell types. 
 
At 14 days after ablation of Zeb1, no significant changes were observed in BM 
and spleen cellularity or spleen size (Supplemental Figure 1A). 
Immunophenotyping of peripheral blood (PB) revealed a significant reduction 
in the proportion of MAC1+ GR1- monocytic cells in Zeb1-/- mice, while no 
significant changes were observed in MAC1+ GR1+ cells, that contain 
granulocytes, or in T cells and B cells in PB or BM (Figure 1E and 
Supplemental Figure 1B) (26, 27). Intriguingly, despite incomplete deletion of 
Zeb1 in lymphoid cells from Zeb1-/- mice, we observed a selective reduction in 
CD8+ effector memory (CD8+ EM) (CD44high CD62L-) T cells in PB and BM of 
Zeb1-/- mice (Figure 1, F and G). We also found a reduction in CD8+ central 
memory (CD8+ CM) (CD44high CD62Lhigh) T cells in spleen of Zeb1-/- mice, 
collectively demonstrating a critical role of Zeb1 in CD8+ T cell function (Figure 
1H).   
 
Acute loss of Zeb1 results in a cell survival defect during thymocyte 
differentiation and a cell-autonomous T cell differentiation defect 
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Having shown a defect in CD8+ T cells in Zeb1-/- mice and given that germ-line 
KO of Zeb1 results in a developmental defect in the T cell lineage (12, 13), we 
opted to assess T cell development in the thymus of adult Zeb1-/- mice. 
Fourteen days after the last dose of pIpC, Zeb1-/- mice displayed diminutive 
thymi coupled with a dramatic reduction in cellularity (Figure 2, A-C). 
Immunophenotypic analysis of T cell subsets in the thymus revealed an 
increased frequency of immature double negative CD4- CD8- (DN) cells and 
mature single positive (SP) CD4 (CD4+) and SP CD8 (CD8+) T cells contrasting 
with a significant reduction in the proportion of double positive CD4+ CD8+ (DP) 
cells in Zeb1-/- mice (Figure 2, D and E). Normalizing for reduced thymic 
cellularity in Zeb1-/- mice led to a significant reduction in total cell numbers 
observed in DN, DP, CD4+ and CD8+ cells from Zeb1-/- mice (Figure 2F).  This 
correlates with increased apoptosis in DP, CD4+ and CD8+ populations but, 
surprisingly, not in DN cells from Zeb1-/- mice (Supplemental Figure 1C). 
 
Given that the earliest stages of T cell development were affected by Zeb1 
ablation, we further evaluated the DN cell compartment, which represents the 
initial stage of thymocyte selection (28, 29). Using CD44 and CD25, the DN 
population can be subdivided chronologically into 4 populations: DN1 (CD44+ 
CD25-), DN2 (CD44+ CD25+), DN3 (CD44- CD25+), and DN4 (CD44- CD25-) 
(29) before they become DP cells and ultimately CD4+ or CD8+ mature cells 
(29). Immunophenotypic analysis showed increased frequency of DN1 cells 
and a reduction in DN2 and DN3 while no change was observed in the 
frequency of DN4 in Zeb1-/- mice, suggestive of a Zeb1 mediated differentiation 
block in the transition between DN1 and DN2/DN3 (Figure 2, G-H). Analysis of 
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apoptosis in DN subsets revealed increased apoptotic levels in DN2 and DN3 
after Zeb1 deletion, accounting for the differentiation block observed in these 
compartments, whereas DN1 and DN4 displayed comparable levels of 
apoptosis between genotypes (Supplemental Figure 1D). When the absolute 
number of these populations was quantified to account for reduced thymic 
cellularity of Zeb1-/- mice, a significant decrease was found across all DN 
populations following Zeb1 deletion (Figure 2I).   
 
Next, we evaluated whether the defect observed within immature DN cells was 
caused by a failure of thymocyte survival preceding selection. We therefore 
assessed early thymic progenitors (ETPs), characterized as CD4- CD8- CD44+ 
CD25- C-KIThigh (30-33). Fourteen days after the last dose of pIpC, we found a 
comparable frequency of ETPs between control and Zeb1-/- mice (Figure 2J) 
with the absolute count of ETPs in Zeb1-/- thymus showing a near significant 
reduction compared to control due to reduced thymic cellularity in Zeb1-/- mice 
(Figure 2K).  
 
Since the Mx1-Cre system deletes genes in non-hematopoietic tissues, such 
as BM niche cells (25, 34), we assessed whether Zeb1 mediated regulation of 
T cell development was cell-autonomous by competitively transplanting 
CD45.2+ BM cells from Zeb1fl/fl;Mx1-Cre+ or control mice, admixed with 
unfractionated CD45.1+ BM cells (Supplemental Figure 2A). Six weeks post-
transplantation Zeb1 deletion was induced by injection of pIpC and 14 days 
after the last pIpC injection analysis of donor engraftment in the thymus 
revealed a dramatic reduction in the Zeb1-/- genotype compared to control 
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(Supplemental Figure 2B). Consistent with this, a substantial attenuation in 
donor contribution to DN, DP, CD4+, and CD8+ cell population were detected in 
the Zeb1-/- genotype (Supplemental Figure 2C). With the exception of ETPs, 
a significant reduction in donor contribution was found across nearly all DN 
populations following cell-autonomous Zeb1 deletion, confirming that Zeb1 
mediates T cell maturation in a cell-autonomous manner (Supplemental 
Figure 2D). Since mature T cell frequency did not change 14 days after Zeb1 
loss during steady state due to incomplete Zeb1 deletion (Figure 1D), we also 
analyzed the donor contribution to peripheral T cells 14 days after Zeb1 ablation 
in a cell-autonomous manner, which revealed complete deletion of Zeb1 and a 
significant reduction in mature T cells in PB, BM, and spleen (Supplemental 
Figure 2, E and F). Further, we confirmed that Zeb1 mediates cell-autonomous 
reduction in EM CD8+ T cells in PB (Supplemental Figure 2G). Together, these 
data suggest that Zeb1 is critical for cell survival at the earliest stages of 
thymocyte differentiation as well as for T cell maturation and maintenance in 
the thymus. Thus, Zeb1 is required for cell-autonomous T cell development in 
the thymus.  
 
Acute conditional deletion of Zeb1 results in a reduction of lymphoid 
lineage commitment in BM 
We next gauged the impact of Zeb1 on early T-lymphoid lineage commitment 
in the BM. LSK CD135high CD127high lympho-myeloid multipotent progenitors 
(LMPPs CD127+, non-conventional LMPP) rapidly and efficiently generate T 
and innate lymphoid cells (35) compared with conventional LMPP (LSK CD34+ 
CD135high) (36)  or HPC1 (LSK CD150- CD48+) that overlap functionally with 
 10 
conventional LMPP by 80% (37-39). Interestingly, we found a significant 
reduction in the proportion of T-cell lineage primed LMPP CD127+ but not 
conventional LMPP, which showed a statistically insignificant trend towards 
reduction after acute Zeb1 ablation (Figure 3, A and B and Supplemental 
Figure 3A). We assessed other BM lymphoid progenitor compartments, 
including CLP (LIN- SCA-1low C-KITlow CD127high CD135high) (35, 40) and LIN- 
SCA-1+ C-KIT- (LSK-) CD135+ CD127+) (41) that were reduced in Zeb1-/- mice 
(Figure 3, A and B). Together, these data suggest that Zeb1 acts as a critical 
modulator of incipient lymphoid progenitor commitment from HSCs. 
 
Acute conditional deletion of Zeb1 in HSCs results in a profound self-
renewal and multi-lineage hematopoietic differentiation defect  
To directly assess the impact of acute deletion of Zeb1 in HSCs, we performed 
flow cytometry analysis on immunophenotypically defined HSCs and all 
multipotent progenitor populations from control or Zeb1-/- mice. The frequency 
of HSCs (LSK CD150+ CD48-) and MPPs (LSK CD150- CD48-) was comparable 
between control and Zeb1-/- genotypes (Supplemental Figure 3B). HPC1 (LSK 
CD150- CD48+) showed a non-significant reduction after Zeb1 deletion similar 
to that observed in conventional LMPP (LSK CD34+ CD135+) (Supplemental 
Figure 3, A and B). Zeb1-/- HPC2 (LSK CD150+ CD48+), which possesses both 
myeloid and lymphoid potential (38), showed a significant reduction in the 
frequency in total BM compared to control (Supplemental Figure 3B). These 
data demonstrate that Zeb1 regulates the abundance of select multipotent 
progenitor populations. 
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Having observed a reduction of MAC1+ GR1- myeloid cells in PB following acute 
deletion of Zeb1 in the hematopoietic system, we asked whether this was due 
to defects in committed myeloid progenitors from BM Zeb1-/-. No significant 
difference in CMP (LK CD34+ CD16/32-), GMP (LK CD34+ CD16/32+) and MEP 
(LK CD34- CD16/32-) populations was noted between control and Zeb1-/- mice 
(Supplemental Figure 3C). Thus, Zeb1 mediated regulation of terminal MAC1+ 
GR1- myeloid cell differentiation appears to be independent of committed 
myeloid progenitor maturation from BM.  
 
To stringently test the functionality and differentiation capacity of HSCs from 
Zeb1-/- mice, we prospectively isolated 150 HSCs (CD45.2) from control or 
Zeb1-/- mice at 14 days following deletion, mixed them with 2x105 BM competitor 
cells (CD45.1) and transplanted this cell preparation into lethally irradiated 
recipients (CD45.1) (Figure 3C). The engraftment capacity of transplant 
recipients in PB was monitored until week 16 (Figure 3C). Significant 
engraftment failure was observed by week 6 and continued to decrease 
progressively until week 16 (Figure 3D). To test the donor contribution to PB of 
specific hematopoietic lineages, we analyzed PB for CD45.2 (donor) and 
CD45.1 (competitor) in conjunction with MAC1+ GR1- myeloid, MAC1+ GR1+ 
myeloid, B220+ B cells, and CD4+/CD8+ T cells. A profound reduction in donor 
contribution to B cells (Figure 3E), MAC1+ GR1- myeloid cells (Figure 3F), and 
MAC1+ GR1+ myeloid cells (Figure 3G) was observed in recipients of Zeb1-/- 
HSCs. No engrafted T cells were derived from recipients transplanted with 
Zeb1-/- HSCs (Figure 3H).  
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Having observed multi-lineage defects in terminally differentiated blood cells in 
recipients of Zeb1-/- HSCs, we asked whether these defects originated in 
parental HSPCs or lineage-committed progenitors. Within LSK compartments, 
the donor contribution to HSC was equal between recipients of control or Zeb1-
/- HSCs (Figure 3I). However, there was a significant reduction in the donor 
contribution to MPP, HPC1, and HPC2 in Zeb1-/- compared to control (Figure 
3I). We also analyzed committed progenitors downstream of HSPCs and found 
a dramatic reduction in donor contribution to CMP, GMP, MEP, and LSK- 
CD127+ but no change was observed in donor contribution to CLP (Figure 3J). 
These data directly link the functional defects observed after transplantation of 
Zeb1 deficient HSCs to alterations in specific HSPC and lineage committed 
progenitor compartments. 
 
An integral part of successful engraftment after BM transplantation is homing 
of intravenously infused HSPCs to the BM niche, the main home of adult 
hematopoiesis. To assess whether the Zeb1-/- engraftment defect was due to 
abnormal homing of Zeb1-/- HSPCs to the BM, we transplanted 7x106 total BM 
cells (CD45.2) from control or Zeb1-/- mice into lethally irradiated recipients 
(CD45.1) and analyzed donor cell presence in recipients at 18 hours after 
transplantation (Supplemental Figure 4A). Relative parity was observed in the 
homing capacity of total BM cells or LSK populations in the two genotypes 
(Supplemental Figure 4B). Similarly, homing of donor cells to the spleen and 
thymus was comparable between control and Zeb1-/- genotypes 
(Supplemental Figure 4C). Thus, acute deletion of Zeb1 does not impact the 
homing ability of hematopoietic cells in vivo.  
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To directly test the impact of Zeb1 deletion on the self-renewal capacity of 
HSCs we performed secondary transplantation of Zeb1-/- HSCs. We sorted 300 
HSCs (CD45.2) from control or Zeb1-/- primary recipients and admixed them 
with 3x105 competitor BM cells before transplanting them into lethally irradiated 
recipients. We observed a strong defect in PB engraftment associated with 
multilineage hematopoietic impairment in secondary transplant recipients by 
week 12 (Figure 4, A and B), indicative of a self-renewal defect in Zeb1-/- 
HSCs.    
 
Zeb1 is required for cell-autonomous HSC function  
To assess whether the acute requirement for Zeb1 in maintaining HSC function 
was cell-autonomous, we performed a competitive BM transplantation by 
transplanting 5x105 BM cells from control and Zeb1fl/fl Mx1-Cre+ (CD45.2) mice 
admixed with equal number of WT competitor cells (CD45.1) into lethally 
irradiated recipients (CD45.1). Six weeks later, Zeb1 deletion was induced by 
administering recipients with pIpC and 14 days after the last dose of pIpC, mice 
were sacrificed and 5x105 donor BM cells (CD45.2) from primary recipients (14 
days after Zeb1 ablation) mixed with 5x105 competitor BM cells (CD45.1) were 
transplanted into lethally irradiated recipients (Figure 4C). Sixteen weeks after 
transplantation, we found a dramatic reduction in donor engraftment in PB and 
BM (Figure 4D). Further analysis of donor contribution to PB lineages revealed 
a marked reduction in myeloid cells, and near loss of B and T cells (Figure 4E).  
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To test whether the Zeb1-/- BM microenvironment plays a role in Zeb1-mediated 
HSC regulation, we transplanted 1x106 wild type (WT) BM cells (CD45.1) into 
lethally irradiated control or Zeb1fl/fl Mx1-Cre+ (CD45.2) mice. Six weeks later, 
we injected the recipients with pIpC to delete Zeb1 and analyzed the mice at 
week 16 after the last dose of pIpC (Supplemental Figure 4D). PB analyses 
of myeloid cells (MAC1+), B cells (B220+), and T cells (CD4+/CD8+) showed no 
significant difference between control and Zeb1-/- (Supplemental Figure 4E). 
Next, we asked whether the altered BM niche would impact the composition of 
HSPC and committed progenitors. The data showed that the frequency of these 
populations was comparable between control and Zeb1-/- (Supplemental 
Figure 4, F and G). Together these data demonstrate that Zeb1 is required for 
cell-autonomous HSC functionality.  
 
Zeb1-/- HSCs display deregulated cell polarity and hematopoietic 
differentiation transcriptional signatures 
In order to understand the transcriptional signature underpinning Zeb1 
mediated regulation in HSCs, we performed RNA sequencing on purified HSCs 
(LSK CD150+ CD48-) from control or Zeb1-/- mice 14 days after the last dose of 
pIpC. From 222 differentially expressed genes (DEG), 47 genes (21%) were 
downregulated and 175 upregulated (79%) from Zeb1-/- HSCs. These data are 
largely consistent with the notion that Zeb1 functions as a transcriptional 
repressor (42).  Biological pathway analysis confirmed that the most enriched 
pathways were upregulated and included tight junction, cell adhesion, cell 
junction organization, immune system and endocytosis pathways (Figure 5A). 
Zeb1 appears to regulate a transcriptional signature related to cell polarity, 
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consisting of genes related to cytoskeleton, cell adhesion and lipid 
metabolism/lipid membrane biology (Figure 5B), congruent with the idea that 
Zeb1 acts as a potent inducer of the EMT process, involving Zeb1-mediated 
repression of cell polarity genes (43-45). Using Ingenuity Pathway Analysis, we 
generated a gene interaction network showing the direct regulation of Zeb1-
specific target genes related to cell polarity, cytoskeleton, and cell adhesion 
that included a regulatory node involving Epithelial cell adhesion molecule 
(EpCAM), CRB3, PARD6b, ITGB4, CDH1, KRT18 and OCLN (10, 43-50) 
(Figure 5C). In agreement with this transcriptional network, EpCAM, CDH1 and 
ITGB4 upregulation in Zeb1-/- HSPCs was confirmed at the protein level by flow 
cytometry (Figure 6, A and B and Supplemental Figure 5, A and B). 
Reflecting the global, multi-lineage differentiation functional defects of Zeb1-/- 
HSCs, we observed a broad, robust pattern of deregulated HSC maintenance 
and hematopoietic lineage-affiliated from both myeloid and lymphoid lineages 
(Figure 5B).  
 
With prominent transcriptional deregulation of T-cell pathways being observed 
in Zeb1-/- HSCs (Figure 5A), we next asked whether the defects in Zeb1-/- HSCs 
could be associated to those observed in Zeb1-/- T cells. To address this 
question at the transcriptional level, we conducted RNA sequencing from Zeb1-
/- or control CLPs, which have T-lymphoid but not myeloid potential, and 
compared their transcriptional signature with that from Zeb1-/- HSCs. Zeb1-/- 
CLPs displayed comparable gene expression pathways to Zeb1-/- HSCs, 
including deregulated cell-cell junction, tight junction, cell adhesion, 
cytoskeleton and T cell pathways (Supplemental Figure 5, C- E). Remarkably, 
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of the 47 differentially expressed genes in Zeb1-/- CLPs, 27 genes (57%) were 
also differentially expressed in Zeb1-/- HSCs (Supplemental Figure 5F). Other 
biological pathways reflecting T-cell function were deregulated in Zeb1-/- HSCs 
but not Zeb1-/- CLPs (e.g. calcium-induced T lymphocyte apoptosis, iCOS-
iCOSL signaling in T helper cells) (Figure 5A). Transcriptional signatures 
relating to the CtBP1 pathway (51, 52) were observed only in Zeb1-/- CLPs 
(Supplementary Figure 5C). However, the majority of transcriptional 
programing mediating the differentiation defect of Zeb1-/- T cells was instigated 
in HSCs and transmitted to CLPs. Overall, in its capacity as a transcriptional 
repressor, Zeb1 acts as a potent regulator of cell polarity and differentiation-
affiliated transcriptional signatures in HSCs. 
 
Increased EpCAM expression confers a cell survival advantage in Zeb1-/- 
HSCs that alters self-renewal and differentiation fates.   
EpCAM, a glycoprotein mediating cell adhesion in epithelia (53), was the most 
highly upregulated gene in Zeb1-/- HSCs (Figure 5B). In other types of stem 
cell, EpCAM has been established as a crucial regulator of stem cell 
maintenance and differentiation (46). We therefore elected to examine the 
impact of EpCAM expression in the context of Zeb1 mediated regulation of HSC 
fate.  We first confirmed enhanced expression of EpCAM at the protein level by 
flow cytometry of Zeb1-/-HSCs, MPP, HPC1 and HPC2 populations (Figure 6, 
A and B). While EpCAM expression was nearly extinguished during 
differentiation to CMP, GMP, MEP committed progenitors, it was upregulated 
in terminally differentiated cells (myeloid, B, and T lineages) from PB (Figure 
6B). EpCAM positive HSPCs from Zeb1-/- LSKs expanded more than their 
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EpCAM negative counterparts in vitro (Figure 6C), suggesting that EpCAM 
expression confers a cell survival signal in Zeb1-/- HSCs. We directly addressed 
whether EpCAM expression mediates cell survival in freshly isolated Zeb1-/- 
HSCs and in vitro and observed reduced apoptosis in Zeb1-/- EpCAM+ HSCs 
and multipotent progenitor subsets in both settings (Figure 6, D and E). Cell 
cycle status based on EpCAM expression was unperturbed in Zeb1-/- HSCs 
(Figure 6F). By evaluating the impact of EpCAM expression in Zeb1-/- HSC 
survival and differentiation in vivo, we showed at 16 weeks after HSC 
transplantation that Zeb1-/- cells in PB displayed a 2-fold increase in EpCAM 
expression compared to controls (Figure 6G). Thus, EpCAM expression in 
Zeb1-/- HSC correlates with the multi-lineage differentiation block observed 
during transplantation (Figure 3 and 4). Yet, high expression of EpCAM was 
preserved in Zeb1-/- HSPCs at 16 weeks after transplant and these EpCAM+ 
Zeb1-/- HSPCs had a lower propensity for apoptosis (Figure 6, H and I). 
Together, these data suggest that augmented EpCAM expression confers a 
cell survival advantage in Zeb1-/- HSCs that causes an imbalance between self-
renewal and differentiation fates.  
 
Zeb1-/- EpCAM+ HSPCs display enhanced cell survival and diminished 
mitochondrial metabolism, RNA biogenesis and differentiation 
transcriptional signatures 
To evaluate the transcriptomic signature demarcating Zeb1-/- EpCAM+ HSPCs 
from Zeb1-/- EpCAM- HSPCs, we performed RNA sequencing on Zeb1-/- 
EpCAM+ LSK cells or Zeb1-/- EpCAM- LSK cells 14 days after the last dose of 
pIpC. 3263 genes were up-regulated and 3153 genes were down-regulated in 
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Zeb1-/- EpCAM+ HSPCs (Figure 7A). In agreement with enhanced cell survival 
and a functional block in differentiation associated with Zeb1-/- EpCAM+ HSCs 
(Figure 6), biological pathway analysis revealed a robust p53 mediated pro-
survival signature and an anti-hematopoietic differentiation signature in Zeb1-/- 
EpCAM+ HSPCs (Figure 7, B-D). Furthermore, we observed augmented 
expression of anti-apoptotic BCL-XL (54) in Zeb1-/- EpCAM+ HSPCs (Figure 7, 
C and E), and an EpCAM-p53-BCL-XL (BCL2L1) interacting gene network of 
apoptotic regulation in Zeb1-/- HSPCs (Supplemental Figure 6).  
 
Mitochondria play crucial regulatory roles in fundamental cellular processes, 
such as apoptosis and bioenergetic provisions (55) and in the context of HSCs 
act as a gatekeeper limiting HSC self-renewal ability (56). Zeb1-/- EpCAM+ 
HSPC displayed reduced mitochondrial gene expression, transport, translation 
and protein import as well as reduced associated mitochondrial metabolic 
pathways (e.g. pyruvate metabolism and TCA cycle) critical to HSC fate (57) 
(Figure 7F). Further highlighting the relatively low bioenergetic state of Zeb1-/- 
EpCAM+ HSPCs, ribosome biogenesis, and ribosome associated pathways, 
such as rRNA processing, whose reduction has previously been associated 
with conferral of stress resistance in pre-leukemic HPSCs (58), were similarly 
downregulated in Zeb1-/- EpCAM+ HSPCs (Figure 7F). Consistent with this, 
Zeb1-/- EpCAM+ HSPCs also displayed augmented acute myeloid leukemia 
signaling (Figure 7F). Therefore, in addition to control of cell survival, Zeb1 
mediated repression of EpCAM appears to be critical in regulating 
mitochondrial metabolism and ribosomal pathways associated with normal 
HSC maintenance and prevention of pre-leukemic and leukemic signaling.  
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ZEB1 expression is downregulated in AML patients and acute deletion of 
Zeb1 in LSCs enhances disease progression in MLL-AF9 and 
Meis1a/Hoxa9 driven AML  
Subversion of HSC fates may cause hematologic neoplasia, including leukemia 
(59). Having found that Zeb1 deficiency leads to critical impairments in HSC 
self-renewal, apoptotic and differentiation fates and because increased EpCAM 
expression in Zeb1 deficient HSCs enhanced AML signaling, we assessed the 
role of Zeb1 in AML. We initially evaluated ZEB1 expression in a large cohort 
of AML patients. AML (n = 2611) and control (n = 77) patient datasets were 
obtained from Gene Expression Omnibus (GEO) to assemble a case/control 
cohort hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChip array 
and analyzed through R using bio-conductor packages, where data was 
normalized using Robust Multi-array Average (RMA). We observed that ZEB1 
expression was lower in AML patients compared to healthy controls (Figure 
8A). Attenuated expression of ZEB1 was particularly prevalent in M4 and M5 
FAB subtypes and, also in AML patients with t(8;21) and MLL chromosomal 
translocations (60, 61) (Figure 8, B and C). Using an independent AML patient 
database (www.bloodspot.eu), we validated lower ZEB1 expression in patients 
harboring these chromosomal translocations (Figure 8D). 
  
While these data imply that ZEB1 acts as a tumor suppressor in AML, the 
functional requirement of Zeb1 in AML disease progression remains unknown. 
To directly assess this, we employed an assay in which leukemic 
transformation of murine C-KIT+ HSPCs is mediated by retroviral 
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overexpression of either MLL-AF9 or Meis1a/Hoxa9 AML oncogenes (62-64). 
MLL-AF9 or Meis1a/Hoxa9-transduced cells were serially passaged for three 
rounds in CFCs to generate pre-LSCs, which, on intravenous injection into 
primary lethally irradiated mice, become LSCs – the malignant counterparts of 
HSCs that drive disease progression in AML (65) (Figure 8E). We co-
transduced HSPCs from non-induced Zeb1fl/fl;Mx1-Cre+ or control mice with 
retroviruses expressing either MLL-AF9 or Meis1a/Hoxa9, collected pre-LSCs 
and transplanted them into primary recipients alongside unfractionated BM 
support cells (Figure 8E). By flow cytometry, we assessed the PB of recipients 
for engrafting leukemic cells and induced Zeb1 deletion with pIpC after disease 
onset, when 20% engraftment of leukemic cells was observed in the PB (66) 
(data not shown). In both MLL-AF9 and Meis1a/Hoxa9 leukemic models, 
recipients of Zeb1 KO LSCs succumbed to AML with enhanced rapidity 
compared to recipients receiving control LSCs, indicating that Zeb1 deletion 
accelerates LSC mediated disease progression (Figure 8, F and G). Thus, 
Zeb1 acts as a tumor suppressor in MLL-AF9 and Meis1a/Hoxa9 AML LSCs.  
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Discussion 
 
Zeb1, in its capacity as a critical EMT regulator, controls myriad processes in 
embryonic development, and through the agency of tissue-specific stem cells, 
acts as a critical regulator of adult tissue homeostasis (18). Deregulation of 
Zeb1 activity has been implicated in multiple cancer types and, in these 
settings, Zeb1 acts as an instigator of the activity of cancer stem cells, a subset 
of cancer cells driving therapy resistance and metastasis, which ultimately 
cause fatality (42, 43). Understanding the cellular and molecular mechanisms 
underpinning Zeb1 mediated regulation of stem cell self-renewal, lineage fate 
and differentiation in normal and cancer stem cells remains incomplete. Here, 
in stem cells of the hematopoietic system, we find that acute conditional 
deletion of Zeb1 causes a profound cell-autonomous self-renewal defect and 
differentiation block across all lineages after transplantation and deregulates a 
transcriptional program associated with cell polarity. Strikingly, acute 
conditional deletion of Zeb1 in HSCs and their progeny affects the lineage fate 
and cell survival of T cells, leading to a rapid loss of thymocytes and CD8+ T-
cell subsets.  
 
While it is known that Zeb1 and other transcription factors, such as zinc finger 
transcription factor Gata3, are essential in T-cell development (67, 68), the 
process in adults is less clear. Here we identify Zeb1 as an indispensable 
regulator of transcriptional programming for the entire adult T-cell repertoire, 
during initial T-cell commitment from HSPC bone marrow progenitor subsets 
through to cell survival during positive and negative selection in the thymus. In 
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spite of incomplete gene deletion using the Mx-Cre system, we also identified 
Zeb1 as a regulator of CD8+ EM in BM and PB and CD8+ CM T cells from 
spleen, supporting previous observations that Zeb1 is critical to CD8+ T cell 
function during infection (69). Our data are also consistent with the notion that 
the ZEB family member Zeb2 plays reciprocal roles in CD8+ T cell biology (69)  
and that it does not compensate for the absence of Zeb1. Further 
understanding Zeb1 mediated control of adult T-cell differentiation may have 
implications for immunosurveillance, a naturally occurring immune mechanism 
involving CD8+ T cells and other immune subsets that eradicate tumor cells (70, 
71). In particular, the complex interplay between the necessity for Zeb1 in 
immune cell subsets involved in immunosurveillance and the tumor 
microenvironment, where paradoxically ZEB1 expression can drive metastasis 
by interfering with immune checkpoints, requires further exploration to negate 
possible toxic effects associated with targeting ZEB1 or ZEB1 target genes 
therapeutically in cancer. Nonetheless, the benefits of modulating the Zeb1 
transcriptional/epigenetic network in cancer immunotherapy have been clearly 
illustrated in the blockade of CD47, a direct transcriptional target of Zeb1, that 
enhances phagocytosis of breast cancer cells undergoing EMT (72).  
 
Zeb1-/- HSCs were functionally defective in their capacity to generate other 
blood lineages in transplantation, suggesting that Zeb1 modulates the ability of 
HSCs to differentiate correctly in vivo through repression of lineage-
commitment affiliated gene programs in HSCs. In keeping with the notion of 
lineage specific transcriptional repression licensed by Zeb1, we observed 
upregulation of 79% of genes in Zeb1-/- HSCs together with a robust gene 
 23 
expression signature associated with de-regulated multi-lineage differentiation. 
Relatively few transcriptional repressors, including Gfi1 and Gfi1b, have been 
shown to regulate HSC self-renewal and differentiation function (73). Gfi1-/- 
HSCs have a phenotype resembling that observed in Zeb1-/- HSCs (74, 75) and, 
notably, both Gfi1 and Gfi1b were transcriptionally repressed in Zeb1-/- HSCs, 
suggesting positive regulation by ZEB1. Zeb1 therefore likely acts as a 
transcriptional repressor that regulates HSC self-renewal and global 
differentiation via a transcriptional repressor network that includes both Gfi1 
and Gfi1b. 
 
Zeb1 regulates HSC self-renewal and differentiation in association with a 
transcriptional program of cell polarity, which relates to the structural and 
cellular changes that occur to a cell, facilitating specialized function, such as 
cell division, adhesion or migration (76). Several studies in Drosophila 
melanogaster male germline stem cells (77, 78) support the long-standing 
hypothesis that cell polarity acts as a critical mechanism that asserts control of 
symmetric versus asymmetric stem cell division and therefore stem cell fate; 
simply put, striking a balance between self-renewal and differentiation fates in 
tissue homeostasis and under conditions of physiologic stress (76, 79). 
Notably, Numb, a marker of asymmetric division in Drosophila melanogaster 
neuroblasts (80), and Crb3, which asymmetrically distributes polarity proteins 
in mouse preimplantation embryos (81) were deregulated in Zeb1-/- HSCs. 
Taken together with the observation that Zeb1-/- HSCs have decreased self-
renewal potential, these data suggesting that Zeb1-/- HSCs favor symmetric, 
differentiating divisions over asymmetric divisions. Other regulators of cell 
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polarity, including genes associated with apical-basal polarity (82), such as 
tight-junctions (Ocln, Marveld2, Tjp3), adherens junctions (Cdh1) and 
desmosomes (Krt8, Dsc2, Dsg2), were upregulated in Zeb1-/- HSCs. We 
provide evidence that de-repression of EpCAM in Zeb1-/- HSCs correlates with 
enhanced HSC survival in homeostasis and transplantation. Yet, enhanced 
HSC survival and relative upregulation of EpCAM in PB correlates with a block 
in engraftment in transplantation of Zeb1-/- HSCs, suggesting that enhanced 
survival of HSCs mediated by EpCAM disturbs the delicate balance of self-
renewal versus differentiation fates.  
 
EpCAM expression in Zeb1-/- HSCs reduced mitochondrial metabolism, which 
is also important for HSC self-renewal, cell survival and differentiation fates 
(57). For example, reduced pyruvate metabolism was observed in EpCAM+ 
Zeb1-/- HSPCs, which is consistent with evidence that ablating aspects of 
pyruvate metabolism causes HSC exhaustion and a block in HSC 
differentiation (83, 84). Associated with a low metabolic state, EpCAM+ Zeb1-/- 
HSPCs also exhibited reduced ribosome biogenesis, which may reflect 
enhanced cell survival mediated by the combinatorial lack of p53 target gene 
phosphorylation, stabilization of p53 and reduced rRNA observed in EpCAM+ 
Zeb1-/-  HSPCs (58, 85). In future work, it will be of interest to further evaluate 
the genetic requirement for EpCAM in Zeb1 mediated HSC function in the 
context of mitochondrial metabolism and ribosome biogenesis.   
 
Deregulation of cell adhesion molecules or other cell polarity genes, such as 
EpCAM, which are a normal feature of epithelial cells, could also be 
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incompatible with the predominantly mesenchymal milieu of the BM 
environment and may facilitate aberrant, cell-autonomous driven interactions of 
HSCs with components of the BM niche (86) . This could restrain the motility or 
alter survival and quiescence of HSCs (or HSPC subsets) within the BM. 
Studies should be conducted utilizing in vivo imaging of Zeb1-/- HSCs in their 
BM habitat to define the broader role of cell polarity related molecules in 
vascular and osteoblastic BM niches and how they might influence HSC fate.   
 
Perturbation of cell polarity is also a hallmark of cancer development (87) and 
given our findings of Zeb1’s impact on myeloid differentiation – which is blocked 
in AML – we explored the function of Zeb1 in AML. In hematologic malignancies 
Zeb1 has variably been reported as either a tumor suppressor (in Sézary 
syndrome and adult T-cell leukemia/lymphoma) (88-90) or an oncogene (in 
mantle cell lymphoma) (91). We found ZEB1 expression was reduced in select 
AML patient subtypes, including those involving MLL chromosomal 
translocations that confer poor prognosis in AML (92). Induction of Zeb1 KO in 
LSC mouse models of MLL-AF9 and Meis1a/Hoxa9-driven AML accelerated 
disease progression, implying that Zeb1 acts as a tumor suppressor in AML 
LSCs. In support of this, ablating pro-oncogenic Gata2 in AML LSCs caused 
upregulation of Zeb1 expression (66). Taken together with analysis of Zeb1-/- 
HSCs, these data suggest that Zeb1 mediated control of HSC self-renewal, 
apoptosis and differentiation fates is integral to suppressing their vulnerability 
to leukemic transformation and disease progression in AML. This view is in 
agreement with the likely pre-leukemic selective advantage provided by 
decreased ribosome biogenesis (58) and enhanced AML signaling in Zeb1-/- 
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EpCAM+ HSPCs. To the contrary, however, and consistent with an oncogenic 
function for Zeb1 in AML, high expression of Zeb1 has been found to drive 
dissemination of AML LSCs and leukemic cells to extramedullary sites and 
other organs (92). Yet, the cell context dependent requirement for Zeb1 in 
initiating and propagating AML (93) remains ambiguous and requires further in-
depth experimentation. 
 
  
 27 
Methods and Materials 
 
Mice 
We have generated Zeb1fl/fl mice (23) which were bred with Mx1-Cre+/- mice 
(25) to generate an experimental cohort of Zeb1fl/fl Mx1-Cre-/- (control) and 
Zeb1fl/fl Mx1-Cre+/- (Zeb1-\-). Zeb1 was deleted after intraperitoneal (IP) 
administration of Polyinosinic:polycytidylic acid (pIpC) (6 doses every alternate 
day, 0.3 mg per dose, GE Healthcare).  All experiments were performed under 
the regulations of the UK Home Office. Genotyping is described in 
Supplemental Methods.  
 
Flow cytometry analysis 
Bones (femurs, tibias, iliac bones) were crushed using a pestle and mortar in 
phosphate-buffered saline (PBS) supplemented with 2% fetal bovine serum 
(FBS) and the BM cell suspension was filtered through 70 μm cell strainer 
(Miltenyi Biotec). Spleen and thymi were minced through 70 μm cell strainer to 
obtain a homogeneous cell suspension. PB was obtained from the tail vein in 
EDTA treated tubes (Starstedt). Red blood cells were lysed by ammonium 
chloride solution (StemCellTechnologies). For the immunophenotypic analysis, 
cells were stained as follows: for HSPCs (LSK SLAM): Lineage cocktail was 
prepared from a pool of biotinylated antibodies of differentiated cell markers in 
PBS 2% FBS (MAC1 and GR1 for myeloid cells, TER119 for erythroid lineage, 
B220 for B cells, CD3e, CD4, CD8a for T cells), SCA-1-APCCy7, C-KIT-APC, 
CD150-PECy7, and CD48-FITC to study HSC, MPP, HPC1, and HPC2; for the 
committed progenitors (LK) LIN cocktail as in LSK SLAM, SCA-1-APCCy7, 
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CKIT-APC, CD34-FITC, CD16/32-PECy7, CD135-PE, and CD127-BV650 to 
study LMPP, CMP, GMP, MEP, and CLP.  The lineage cocktail was detected 
by adding streptavidin as a secondary antibody. Lineage positive cells from the 
BM and spleen were stained for GR1-PECy7 and MAC1-APC (myeloid cells), 
CD3-APC, CD4-PE, CD8-APCCy7 (T-cells), B220-FITC (B-cells), CD62L-
PECy7, CD44-APC (naïve, effector, and memory T cells). For thymocytes, cells 
were stained for CD4 and CD8, CD44, CD25 and C-KIT to study early and late 
stages of T cell development in thymus. For apoptosis assay, after staining the 
cells for cell surface markers, they were stained with Annexin V-PE antibody 
(BioLegend) for 30 minutes in the dark at RT and diamidino-2-phenylindole 
(DAPI 1 μg/ml) (Molecular probes) was added before running the samples. Ki67 
for cell cycle analysis in HSCs and intracellular staining were done after the 
extracellular staining, the cells were fixed in 1% paraformaldehyde (PFA) 
(ThermoFisher) for 20 minutes at 4oC, permeabilized using PBS containing 
0.1% Saponin (Sigma) for 30 minutes at 4oC, and then stained with the 
antibodies for 30 minutes at 4oC in dark. For cell cycle, cells were incubated 
with DAPI at final concentration of 5 ug/mL in dark for 5 minutes before running 
the samples. Samples were analyzed using BD LSRFortessaTM (BD 
Biosciences). Data were analyzed using FlowJo 10.0.8 (Tree Star, Inc).  A full 
list of antibodies used is shown Supplemental Table 1. 
 
For HSC sorting, BM cell suspension was obtained and red blood cells were 
lysed by ammonium chloride solution (StemCellTechnologies). Cells were 
enriched for CKIT by magnetic-activated cell sorting (MACS) (MACS®, Miltenyi 
Biotec) using anti-CKIT magnetic beads (Miltenyi Biotec).  CKIT+ cells were 
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stained as described earlier and HSCs were sorted using a BD FACSAriaTM 
Fusion (BD Biosciences). 
 
Transplantation experiments 
C57BL/6 SJL mice (CD45.1) were used as recipients for all the transplantations 
except for the niche transplantation C57BL/6 (CD45.2) mice (The Jackson 
Laboratory, Bar Harbor, ME USA) were used as recipients.  The mice were 
lethally irradiated at 9 Gy (split dose).  For primary transplantation, 150 HSCs 
from Zeb1-/- and control cells mixed with 2X105 whole BM (CD45.1) (supporting 
cells) were intravenously transplanted into lethally irradiated mice (CD45.1).  To 
monitor the engraftment, tail vein bleeding was performed at different time 
points post-transplant. To further assess the capacity of Zeb1-deficient HSCs 
to repopulate secondary recipients, 300 HSCs from Zeb1-/- and control mixed 
with 3 x105 whole BM (CD45.1) (supporting cells) were intravenously 
transplanted into lethally irradiated mice (CD45.1).  The engraftment ability was 
monitored via tail vein bleeding as was done with the primary recipients.   
 
For cell autonomous transplantation, Zeb1 was deleted specifically in 
hematopoietic cells (but not in BM niche cells) after transplanting 5X105 whole 
BM (CD45.2) from Zeb1fl/fl Mx1-Cre+ and Zeb1fl/fl Mx1-Cre- along with 5X105 
whole BM (CD45.1) (supporting cells) into lethally irradiated recipients 
(CD45.1).  Six weeks later, 6 doses of pIpC (every alternate day, 0.3 mg per 
dose) were intraperitoneally (IP) injected to delete Zeb1.  Mice were dissected 
at day 14 after the last dose of pIpC and analyzed. For the cell autonomous 
secondary transplantation, 5x105 CD45.2 donor BM cells were sorted from 
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control and Zeb1-/- primary recipients and mixed with competitor cells and re-
transplanted into lethally irradiated recipients. 
 
For niche transplantation, 1 x106 total BM cells from wild type CD45.1+ mice 
were transplanted into lethally irradiated Zeb1fl/fl Mx1-Cre+ and Zeb1fl/fl Mx1-Cr-
mice. Six weeks later, 6 doses of (every alternate day, 0.3 mg per dose) were 
IP injected to delete Zeb1.  Mice were dissected at week 16 after the last dose 
of pIpC. 
 
Leukemia transformation assay 
1X106 CD45.2+ C-KIT+ cells were obtained from control and Zeb1fl/fl Mx1-Cre-/+ 
mice and cultured in IMDM 10% FBS supplemented with 40 ng/mL SCF, 20 
ng/mL IL-3, and 20 ng/mL IL-6. The next day, the cells were transduced with 
retroviral vectors encoding Meis1a/Hoxa9 and MLL-AF9 using retronectin-
coated plates (TaKaRa) as described previously (64, 66). After 72 hours, 5,000 
cells were plated in colony forming units assay 1 (CFC1) using MethoCult™ 
M3231 (STEMCELL Technologies) semi-solid media for 6 days and this 
process repeated for up to 3 rounds of CFCs. At the end of CFC3, pre-LSCs 
were harvested and sorted according to C-KIT expression and transplanted into 
lethally-irradiated primary recipients. Three weeks later, Zeb1 was deleted after 
IP administration of pIpC (8 doses every alternate day, 0.3 mg per dose, GE 
Healthcare). Mice were monitored for AML development.   
 
RNA-sequencing  
RNA from HSCs (LSK CD150+ CD48- ) and CLP (LIN- SCA-1low C-KITlow 
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CD127+) from control and Zeb1-/- mice 14 days after the last dose of pIpC 
injection was extracted using RNAeasy micro kit (Qiagen). Total RNA quality 
and quantity was assessed using Agilent 2100 Bioanalyzer and RNA Nano 
6000 kit (Agilent Technologies). The library was prepared using the NEB® 
Ultra™ II Directional RNA Library Prep Kit for Illumina® (NEB). The libraries 
then were sequenced using a 75-base paired-end (2x75bp PE) dual index read 
format on the Illumina® HiSeq4000 according to the manufacturer’s 
instructions. Further details on sequencing and bioinformatics were described 
previously (66). 
 
The heatmap was created using Morpheus, an online tool, (Broad Institute). 
Differentially expressed genes (DEGs) according to FDR <0.05 were used for 
heatmaps. The biological pathway analysis was performed using BioCarta, 
KEGG and Reactome pathway databases run on GSEA software (94) as well 
as Ingenuity Pathway Analysis software (IPA) (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathwayanalysis). 
IPA was used to create a prediction network of Zeb1 interactions with its target 
genes.  
 
RNA sequencing for EPCAM+ and EPCAM- from Zeb1-/- mice is described in 
Supplemental Methods. 
 
All RNA-sequencing data can be accessed at the GEO (GSE153664, 
GSE154615). 
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AML patients bioinformatic analysis 
A cohort of 2611 AML and 77 control were obtained from GEO (GSE14468, 
GSE22845, GSE10358, GSE12417, GSE13159, GSE14062, GSE15434, 
GSE16015, GSE38987, GSE22056, GSE33223, GSE17855, GSE15389)  (95) 
and ArrayExpress (E-MTAB-3444) (96). R software was used to analyze and 
produce data. Data processing, normalization, and analysis were described 
previously (97). 
 
Statistical Analysis 
Figures were prepared using Prism (GraphPad Software, Inc.). Statistical 
analyses were done using Mann–Whitney U test to calculate significance as 
follows: *P < .05, **P < .01, ***P < .001, ****P <0.0001. 
 
Study Approval 
All animal experiments were performed according to protocols ratified by the 
UK Home Office and carried out at Cardiff University animal facility under 
project number 30/3380. 
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Figure 1. Loss of Zeb1 impacts effector and central memory CD8+ T cells. 
(A) RT Q-PCR analysis of mRNA Zeb1 expression in different hematopoietic 
populations (n=6-7 except CLP n=3). (B)  A scheme of pIpC treatment to delete 
Zeb1 in Zeb1fl/fl Mx1-Cre- (control) and Zeb1fl/fl Mx1- Cre+ (Zeb1-/-) mice and 
analysis at D14 after the last pIpC dose. (C) Representative gel electrophoresis 
analysis confirming Zeb1 deletion in BM cells and LSK population 14 days after 
the last dose of pIpC. (D) Representative gel electrophoresis analysis of Zeb1 
deletion in BM C-KIT+ cells, spleen B (B220+) and T (CD3+) cells 14 days after 
the last dose of pIpC.  (E) The frequency of differentiated cells in PB from 
control and Zeb1-/- mice 14 days after the last dose of pIpC from 4 independent 
experiments (n= 8-12 per group). (F) The gating strategy of naïve, effector 
memory (EM) and central memory (CM) T cells using CD62L and CD44 
markers along with T cell markers CD3, CD4, and CD8 in PB. The frequency 
of EM T cells (G) and CM T cells (H) within CD3+ CD8+ T cells in PB, BM, and 
SP from control (n= 5 PB and BM, 6 SP) and Zeb1-/- (n= 5 PB and BM, 6-7 SP 
) mice from 2 independent experiments. Error bars show mean ± SEM. Mann-
Whitney U test was used to calculate significance as follows: *P < .05, **P < 
.01, ***P < .001, ****P <0.0001. 
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Figure 2. Loss of Zeb1 results in T cell reduction in thymus associated 
with early differentiation defects in thymus. Thymus weight (A), a 
representative picture (B) and total thymus cellularity (C) from control (n=9) and 
Zeb1-/- (n=8) mice from 5 independent experiments at D14 after the last pIpC 
dose. (D) Representative FACS plots of T cell analysis in thymus based on CD4 
and CD8 cell surface markers (DN: CD4- CD8- , DP: CD4+ CD8+, CD4+, CD8+). 
(E) Frequency of T cell subsets in thymus from control (n=13) and Zeb1-/- (n=12) 
mice from 6 independent experiments at D14 after the last pIpC dose. (F) Total 
cell count of T cell subsets in thymus from control (n=14-15) and Zeb1-/- (n=14-
15) mice from 7 independent experiments at D14 after the last pIpC dose. (G) 
Representative FACS plots showing the gating strategy of early stages within 
CD4 CD8 DN population using CD25 and CD44 (DN1: CD44+ CD25-, DN2: 
CD44+ CD25+, DN3: CD44- CD25+, DN4: CD44- CD25-) between control and 
Zeb1-/- at D14 after the last pIpC dose. (H) Frequency of DN populations (DN1, 
DN2, DN3, DN4) in DN cells from control (n=12) and Zeb1-/- (n=12) mice from 
5 independent experiments at D14 after the last pIpC dose.  (I) Total cell count 
of DN populations in thymus from control (n=9-13) and Zeb1-/- (n=11-13) mice 
from 4 independent experiments at D14 after the last pIpC dose. (J) The 
frequency and (K) the total count of ETPs (DN1 cKithigh) from control (n=10) and 
Zeb1-/- (n=10-11) mice from 4 independent experiments at D14 after the last 
pIpC dose. Error bars show mean ± SEM. Mann-Whitney U test was used to 
calculate significance as follows: *P < .05, **P < .01, ***P < .001, ****P <0.0001. 
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Figure 3. Loss of Zeb1 results in a reduction of lymphoid progenitors in 
BM and a multilineage hematopoietic differentiation defect after HSC 
transplantation.  (A) Representative FACS plots of the analysis of LMPP 
CD127+ (non-conventional LMPP: LSK CD135+ CD127+), CLP (LIN- SCA-1low 
C-KITlow CD135+ CD127+), and LSK- CD127+ CD135+ 14 days after the last 
dose of pIpC.  (B) Frequency of LMPP CD127+, CLP, and LSK- CD127+ CD135+ 
in the BM from control (n=8) and Zeb1-/- (n=10) mice from 4 independent 
experiments at D14 after the last pIpC dose.  (C) A scheme of the competitive 
HSC transplantation. 150 HSCs from control or Zeb1-/- mice (donor CD45.2) 
mixed with 2X105 BM competitor cells (CD45.1) were transplanted into lethally 
irradiated recipients (CD45.1) and the mice were monitored by bleeding the tail 
vein at different time points until week 16.  (D) The percentage of donor cells in 
PB at different time points post HSC transplantation from control (n=10) and 
Zeb1-/- (n= 10) mice from 3 independent experiments.  Analysis of PB donor 
contribution to B cells (B220+) (E), MAC1+ GR1- myeloid cells (F), MAC1+ GR1+ 
myeloid cells (G), and T cells (CD4+ CD8+) (H) from control (n=10) and Zeb1-/- 
(n=8-10) mice from 3 independent experiments.  Donor contribution to BM 
HSPCs (I) (HSC: LSK CD150+ CD48- , MPP: LSK CD150- CD48- , HPC1: LSK 
CD150- CD48+ , HPC2: LSK CD150+ CD48+ ) from control (n=9) and Zeb1-/- 
(n=9) from 3 independent experiments and BM committed progenitors (J) 
(CMP: LK CD34+ CD16/32- , GMP: CD34+ CD16/32+ , MEP: CD34- CD16/32- , 
CLP: LIN- SCA-1low C-KITlow CD127+ , and LSK-  CD127+ from control (n=6) and 
Zeb1-/- (n=7) from 2 independent experiments.  Error bars show mean ± SEM.  
Mann-Whitney U test was used to calculate significance as follows: *P < .05, 
**P < .01, ***P < .001, ****P <0.0001. 
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Figure 4. Zeb1 regulates HSC self-renewal and differentiation in a cell 
autonomous manner.  (A) Schema of the secondary HSC transplantation. 300 
CD45.2+ HSCs from primary recipients from control or Zeb1-/- mice mixed with 
3X105 BM competitor cells (CD45.1) were transplanted into lethally irradiated 
recipients (CD45.1) and the mice were analysed at week 12. (B) The 
percentage of donor cells in PB and donor contribution to myeloid (MAC1+), B 
(B220+), and T (CD4+/CD8+) cells at week 12 post-secondary HSC 
transplantation from control (n=7) and Zeb1-/- (n=5) from 2 independent 
experiments.  (C) Schema of the secondary total BM transplantation in cell 
autonomous manner.  5X105 CD45.2+ BM cells from primary recipients 14 days 
after the last pIpC dose from control or Zeb1-/- mice mixed with 5X105 BM 
competitor cells (CD45.1) were transplanted into lethally irradiated recipients 
(CD45.1) and the mice were analysed at week 16.  (D) The percentage of donor 
cells in PB and BM at week 16 post-secondary cell autonomous total BM 
transplantation from control (PB n=5, BM=6) and Zeb1-/- (PB n= 7, BM=6) mice 
from one experiment.  (E) Donor contribution to PB MAC1+ myeloid cells, B220+ 
B cells, and CD4+/CD8+ T cells at week 16 post-secondary cell autonomous 
total BM transplantation from control (n=5) and Zeb1-/- (n=7) mice from one 
experiment. Error bars show mean ± SEM.  Mann-Whitney U test was used to 
calculate significance as follows: *P < .05, **P < .01, ***P < .001, ****P <0.0001. 
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Figure 5. Zeb1-/- HSCs display deregulation of hematopoietic function and 
cell polarity transcriptional programming.  RNA sequencing was performed 
in sorted control and Zeb1-/- HSCs (LSK CD150+ CD48-) 14 days after the last 
pIpC dose (n=4 for each genotype).  (A) Biological pathway analysis shows the 
top enriched pathways in Zeb1-/- HSCs compared to control. Data is shown as 
–log10 (p-value), and the dashed black line indicates p-value = 0.05. (B) Heat 
maps of the differentially expressed genes after Zeb1 deletion related to HSC 
function, T cells and B cells as well as cytoskeleton, lipid metabolism, and cell 
adhesion. The heatmap scale represents Z-score. (C) A network of Zeb1 
interaction with several target genes related to polarity, cytoskeleton, and cell 
adhesion using Ingenuity Pathway Analysis (IPA) software. Due to their 
confirmed binding to ZEB1 in the literature, Epcam, Pard6b, and Crb3 were 
added manually. 
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Figure 6.  Increased EpCAM expression confers survival advantage and 
differentiation block in Zeb1-/- HSCs.  (A) Representative flow cytometry plots 
of EpCAM expression in HSCs 14 days after pIpC injection.  (B) Analysis of 
EpCAM expression in BM subpopulations and PB mature cells 14 days after 
pIpC injection from control (n=8 for HSC, MPP, HPC1, and HPC2; n=4 for 
LMPP, CLP and mature PB populations; n=5 for CMP, GMP, and MEP) and 
Zeb1-/- (n=10 for HSC, MPP, HPC1, and HPC2; n=6 for LMPP and CLP; n= 4 
for mature PB populations except MAC1+ GR1- n=3; n=7 for CMP, GMP, and 
MEP). (C) Cell number after culturing 2500 LSKs from Zeb1-/- EpCAM- (n=6) 
and Zeb1-/- EpCAM+ (n=6) from 3 independent experiments.  (D) Analysis of 
apoptosis in LSKs post culture from Zeb1-/- EpCAM- (n=6) and Zeb1-/- EpCAM+ 
(n=6) from 3 independent experiments. (E) Analysis of apoptosis in fresh BM 
HSPCs 14 days after pIpC injection from Zeb1-/- EpCAM- (n=4) and Zeb1-/- 
EpCAM+ (n=4) from 2 independent experiments. (F) Cell cycle analysis of 
HSCs using Ki67 and DAPI 14 days after pIpC injection from Zeb1-/- EpCAM- 
(n=5) and Zeb1-/- EpCAM+ (n=5) from one experiment. (G) Analysis of EpCAM 
expression in donor PB at week 16 after primary HSC transplantation from 
control (n=5) and Zeb1-/- (n=5) from one experiment represented as fold 
change. (H) Representative FACS plots of the analysis of EpCAM expression 
in LSKs 16 weeks post primary HSC transplantation from control (n=2) and 
Zeb1-/- (n=1) from one experiment. (I) Representative FACS plots of the 
analysis of apoptosis using Annexin V in EpCAM negative and positive fractions 
within donor LSKs 16 weeks post primary HSC transplantation from control 
(n=2) and Zeb1-/- (n=1) from one experiment. Error bars show mean ± SEM.  
Mann-Whitney U test was used to calculate significance as follows: *P < .05, 
**P < .01, ***P < .001, ****P <0.0001. 
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Figure 7. Zeb1-/- EpCAM+ HSPCs display enhanced cell survival and 
diminished mitochondrial metabolism, RNA biogenesis and 
differentiation transcriptional signatures. (A) a volcano plot showing the 
relationship between magnitude of gene expression change (log2 of fold-
change; x-axis) and statistical significance of this change [-log10 of adjusted p-
value; y-axis] in a comparison of Zeb1-/- EpCAM+ to Zeb1-/- EpCAM- LSK cells. 
Coloured points represent differentially expressed genes (cut-off FDR < 0.05) 
that are either overexpressed (red) or under expressed (green) in Zeb1-/- 
EpCAM+ compared to Zeb1-/- EpCAM-. (B) GSEA plots of regulation of 
apoptosis, stabilization of P53, TP53 targets phosphorylated and hematopoietic 
stem cell differentiation. Heat maps of the differentially expressed genes within 
EpCAM+ and EpCAM- LSK after Zeb1 deletion related to anti-apoptosis (C) and 
pro-apoptosis (D). (E) A representative histogram of BCL-XL levels in EpCAM 
fractions within Zeb1-/- LSK. (F) Canonical pathways that mostly enriched in 
Zeb1-/- EpCAM+ LSK cells derived from the IPA, BioCarta, KEGG, PID and 
Reactome pathway databases. Data is shown as –log10 (p-value), and the 
dashed black line indicates p- value = 0.05, the analysis was performed using 
the GSEA software and IPA. 
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Figure 8. Zeb1 is downregulated in AML patient samples and acts as a 
tumour suppressor in MLL-AF9 and Meis1a/Hoxa9-driven AML. (A-C) 
ZEB1 RMA normalised expression from combined published datasets in (A) 
control and AML, (B) across FAB subtypes and, (C) karyotypes. (D) ZEB1 Log2 
expression data in human HSPC and AML karyotypes. Data from Bloodspot 
(www.bloodspot.eu). Error bars show mean ± SEM.  Student t-test was used 
unless otherwise indicated to calculate significance as follows: *P < .05, **P < 
.01, ***P < .001, ****P <0.0001. (E) C-KIT+ cells from control and Zeb1fl/fl Mx1-
Cre+ mice were transduced with retroviruses expressing MLL-AF9 or 
Meis1a/Hoxa9 oncogenes and plated into colony-forming-cell (CFC) assays. 
After CFC3 (6 days each CFC), pre-LSCs (CD45.2+ C-KIT+) were sorted and 
transplanted into lethally-irradiated recipients together with CD45.1+ 
unfractionated BM cells. Three weeks later, mice were administered pIpC to 
induce gene deletion and monitored for AML development. (F and G) Kaplan-
Meier survival curve of primary recipients transplanted with (F) MLL-AF9 (n = 
4) or (G) Meis1a/Hoxa9 (n = 4) preLSCs. Statistical analyses: Mantel-Cox test. 
 
 
